Quartz·1 min read·medium
Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline overhaul
✦AI Summary
Sanofi has decided to discontinue the development of a new eczema drug after determining it would not offer significant clinical improvements over existing treatments. The decision is part of a broader pipeline overhaul led by the company's CEO.
The French drugmaker said the drug would not represent a meaningful improvement over existing treatments, including its own Dupixent
healthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in